---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-038156"
form_type: "8-K/A"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T14:38:02.709512+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics appoints Alan R. Stewart as Class I director

## Summary
- Alan R. Stewart appointed Class I director effective October 10, 2023.
- He also joined the Audit Committee and Compensation Committee.
- Received options to purchase 52,500 shares at $3.32 per share.
- Stewart is CFO of Soundthinking, Inc. with M&A and finance expertise.

## SEC filing metadata
- accession: 0001493152-23-038156
- form_type: 8-K/A
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315223038156/0001493152-23-038156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315223038156/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-038156
- JSON: https://secwatch.observer/filing/0001493152-23-038156.json
- Plain text: https://secwatch.observer/filing/0001493152-23-038156.txt

## Key facts
- Executive change
  Alan R. Stewart was appointed as Class I director at Calidi Biotherapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: On October 10, 2023, the Company announced the appointment of Mr. Alan R. Stewart as the Class I director of the Company, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315223038156/0001493152-23-038156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.